Sickle Cell Disease Treatment Market - By Treatment Modality [Blood Transfusion, Pharmacotherapy (Hydroxyurea, Oxybryta, Endari), Bone Marrow Transplant], By Disease (Sickle Cell Anemia, Hemoglobin Sickle C), By End-user & Forecast, 2023-2032

Description

List of Tables

Global Sickle Cell Disease Treatment Market will have a stable growth rate from 2023-2032. The high prevalence of sickle cell disease, particularly in sub-Saharan Africa and some parts of the Middle East, demands effective treatment options. According to CDC, SCD affects an estimated 100,000 Americans. Also, the disease occurs in about 1 in every 365 Black or African American births.

Advancements in medical research and technology have led to the development of novel therapies, including gene therapies and targeted drugs, improving patient outcomes. In addition, government initiatives and collaborations with pharmaceutical companies have facilitated increased access to treatment options. Moreover, growing awareness among healthcare professionals and patients about the importance of early diagnosis and management of the disease has further fuelled the demand for innovative treatments in the Sickle Cell Disease Treatment Market.

The overall market share is classified based on treatment modality, disease, end-user, and region.

Based on treatment modality, the bone marrow transplant segment will contribute significantly to the market revenue from 2023 to 2032. This treatment option offers a potential cure for sickle cell disease by replacing defective stem cells with healthy ones from a compatible donor. As awareness of this therapeutic approach grows, more patients and healthcare professionals are considering bone marrow transplants as a viable solution. Advances in transplant techniques and a better understanding of matching criteria have improved success rates, making bone marrow transplants an increasingly sought-after option.

By disease, the hemoglobin sickle C disease (HbSC) segment will show a high growth rate from 2023-2032 and could dominate the sickle cell disease treatment market share by 2032. HbSC is a milder form of sickle cell disease, but it can still cause complications and affect the quality of life for affected individuals. As awareness and understanding of HbSC increase, there is a growing need for targeted therapies and supportive care options to manage symptoms and improve patients' overall well-being, which will favor segment growth in the long run.

Regarding end-user, the specialty clinics segment of the sickle cell treatment industry will record a decent valuation by 2032. These clinics offer specialized care and expertise in managing sickle cell disease, providing comprehensive treatment options and support to patients. With a focus on personalized care and tailored treatment plans, specialty clinics play a crucial role in improving patient outcomes and quality of life. The rising awareness of the importance of specialized care for sickle cell disease has led to a growing demand for these clinics in the Sickle Cell Disease Treatment Market.

Regionally, the Europe sickle cell disease treatment market will gain traction during the forecast period due to increasing awareness and improved diagnosis of sickle cell disease in the region. The region's strong healthcare infrastructure and access to advanced medical research and technologies support the development and availability of innovative therapies. Additionally, government initiatives and collaborations with pharmaceutical companies promote research and development in the field. The growing focus on improving patient outcomes and enhancing quality of life drives the demand for sickle cell disease treatment in Europe.

Product Code: 5697

Chapter 1 Methodology & Scope

1.1 Market definitions
1.2 Base estimates and calculations
1.3 Forecast calculations
1.4 Data sources
- 1.4.1 Secondary
  - 1.4.1.1 Paid sources
  - 1.4.1.2 Public sources
- 1.4.2 Primary

Chapter 2 Executive Summary

2.1 Sickle cell disease treatment industry 360 degree synopsis, 2018 - 2032 (USD Million)
- 2.1.1 Business trends
- 2.1.2 Region trends
- 2.1.3 Treatment modality trends
- 2.1.4 Disease type trends
- 2.1.5 End-user trends

Chapter 3 Sickle Cell disease Treatment Market Insights

3.1 Industry landscape, 2018 - 2032 (USD Million)
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of sickle cell disease
  - 3.2.1.2 Increasing R&D activities in drug development for sickle cell disease
  - 3.2.1.3 Increasing healthcare expenditure and government initiatives
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost associated with the treatment
  - 3.2.2.2 Side effects associated with sickle cell disease treatment drugs
3.3 Growth potential analysis
- 3.3.1 By treatment modality
- 3.3.2 By disease type
- 3.3.3 By end-user
3.4 COVID-19 impact analysis
3.5 Clinical trial analysis
3.6 Regulatory landscape
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Global company market share analysis, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022

Chapter 5 Sickle Cell Disease Treatment Market Estimates and Forecast, By Treatment Modality (USD Million)

5.1 Key trends, by treatment modality
5.2 Blood transfusion
5.3 Pharmacotherapy
- 5.3.1 By drug type
  - 5.3.1.1 Hydroxyurea
  - 5.3.1.2 Oxybryta
  - 5.3.1.3 Adakveo
  - 5.3.1.4 Endari
  - 5.3.1.5 Other pharmacotherapies
- 5.3.2 By route of administration
  - 5.3.2.1 Oral
  - 5.3.2.2 Parenteral
5.4 Bone marrow transplant

Chapter 6 Sickle Cell Disease Treatment Market Estimates and Forecast, By Disease Type (USD Million)

6.1 Key trends, by disease type
6.2 Sickle cell anemia
6.3 Hemoglobin sickle C disease (HbSC)
6.4 Other disease types

Chapter 7 Sickle Cell Disease Treatment Market Estimates and Forecast, By End-user (USD Million)

7.1 Key trends, by end-user
7.2 Hospitals
7.3 Specialty clinics
7.4 Other end-users

Chapter 8 Sickle Cell Disease Treatment Market Estimates and Forecast, By Region (USD Million)

8.1 Key trends, by region
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Switzerland
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East & Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 Rest of MEA

Chapter 9 Company Profiles

9.1 Pfizer, Inc.
9.2 Novartis AG
9.3 Emmaus Medical, Inc.
9.4 Medunik USA, Inc.
9.5 Bristol-Myers Squibb Company
9.6 Bluebird Bio, Inc.
9.7 Agios Pharmaceuticals
9.8 CRISPR Therapeutics
9.9 Vifor Pharma
9.10 Editas Medicine Inc.